GlassScriptPhysician profile
Sydney Grey
NPI 1912548140
$6,482.47
in general payments reported to CMS, 2019-2025
30 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,007 · 2022: $1,030 · 2023: $1,085 · 2024: $1,507 · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,345 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,345.18 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.12 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $655.68 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $608.19 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $492.48 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $485.59 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Jazz Pharmaceuticals INC. | $444.64 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $365.81 | 2024-2025 | Lumryz |
| Neurelis, INC. | $356.85 | 2024-2025 | Valtoco |
| Alkermes, INC. | $308.00 | 2021-2024 | Aristada, Lybalvi |
| Corium, LLC | $238.33 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $206.14 | 2025 | Jornay Pm |
| Ucb, INC. | $190.11 | 2024-2025 | Fintepla, Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $165.96 | 2021-2024 | Austedo Xr, Uzedy |
| Ironshore Pharmaceuticals INC. | $150.44 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $142.06 | 2021-2024 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $121.32 | 2021-2025 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $105.23 | 2021-2023 | Trintellix |
| Tris Pharma INC | $98.82 | 2024-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $87.60 | 2023-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $78.32 | 2021-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $56.83 | 2022 | |
| Noven Therapeutics, LLC | $45.56 | 2024-2025 | Xelstrym, Secuado |
| Harmony Biosciences LLC | $32.44 | 2025 | |
| Xeris Pharmaceuticals, INC. | $31.66 | 2025 | Keveyis |
| Owp Pharmaceuticals, INC. | $23.53 | 2022 | |
| Sunovion Pharmaceuticals INC. | $22.28 | 2022 | |
| Vertical Pharmaceuticals, LLC | $21.27 | 2025 | Relexxii |
| Lilly USA, LLC | $16.38 | 2025 | Zepbound |
| Almatica Pharma LLC | $16.20 | 2023 | Loreev Xr |
| Azurity Pharmaceuticals, INC. | $15.63 | 2025 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Grey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.